Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Jan 8;30(2):519–530. doi: 10.1038/s41591-023-02758-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024, corrected publication 2024

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 5 — a, Kaplan-Meier plots of DFS stratified by ctDNA-negative and ctDNA-positive status or b, ctDNA clearance and no clearance at the pre-surgery time point. HRs and 95% CIs were calculated using the Cox proportional hazard model. Significance was calculated using the two-sided log-rank test. c, Association between pathologic response and ctDNA dynamics from baseline, after monotherapy atezolizumab and before surgery (n = 16). Group allocation: ctDNA +/+/+: no clearance prior to surgery; ctDNA +/+/−: clearance prior to surgery; ctDNA +/−/−: clearance after monotherapy atezolizumab. Significance was tested using one-sided Fisher’s exact test. d,e, Kaplan-Meier plots of DFS stratified by ctDNA-negative and ctDNA-positive status at the MRD (d) or follow-up (e) time point post-surgery. To account for immortal time bias, a landmark analysis was performed 12 weeks after surgery (d) and from the last ctDNA follow-up time point after surgery (e). HRs and 95% CIs were calculated using the Cox Regression with Firth’s Penalized Likelihood hazard model. Significance was calculated using a two-sided log-rank test. MRD: Molecular Residual Disease.